Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice

Hepatology

Volumn 53, Issue 3, 2011, Pages 895-904

  Aleksic, Kristina ^a   Lackner, Carolin ^a   Geigl, Jochen B ^a   Schwarz, Martina ^b   Auer, Martina ^a   Ulz, Peter ^a   Fischer, Maria ^a,c   Trajanoski, Zlatko ^a,c   Otte, Marcus ^a,b   Speicher, Michael R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b ORIDIS Biomed GmbH   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DIETHYLNITROSAMINE; KI 67 ANTIGEN; TRANSCRIPTION FACTOR RUNX3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CHROMOSOMAL INSTABILITY; CHROMOSOME 4Q; CHROMOSOME 6Q; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; LASER MICRODISSECTION; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 79952238282     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24133     Document Type: Article

References (46)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
4. Bruix J, Llovet JM. Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis 2010; 30: 1-2.
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
6. Kojiro M. Pathological diagnosis at early stage: reaching international consensus. Oncology 2010; 78(Suppl 1): 31-35.
7. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30: 17-25.
8. Fausto N, Campbell JS. Mouse models of hepatocellular carcinoma. Semin Liver Dis 2010; 30: 87-98.
9. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71: 57-81.
10. Farber JL, Gerson RJ. Mechanisms of cell injury with hepatotoxic chemicals. Pharmacol Rev 1984; 36: 71S-75S.
11. Sarma DS, Rao PM, Rajalakshmi S. Liver tumour promotion by chemicals: models and mechanisms. Cancer Surv 1986; 5: 781-798.
12. Bralet MP, Pichard V, Ferry N. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. HEPATOLOGY 2002; 36: 623-630.
13. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
14. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-1311.
15. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-990.
16. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001; 20: 7812-7816.
17. Kim SE, Yoon JY, Jeong WJ, Jeon SH, Park Y, Yoon JB, et al. H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation. J Cell Sci 2009; 122: 842-848.
18. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778-3786.
19. Hacker HJ, Mtiro H, Bannasch P, Vesselinovitch SD. Histochemical profile of mouse hepatocellular adenomas and carcinomas induced by a single dose of diethylnitrosamine. Cancer Res 1991; 51: 1952-1958.
20. Geigl JB, Speicher MR. Single-cell isolation from cell suspensions and whole genome amplification from single cells to provide templates for CGH analysis. Nat Protoc 2007; 2: 3173-3184.
21. Begus-Nahrmann Y, Lechel A, Obenauf AC, Nalapareddy K, Peit E, Hoffmann E, et al. p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nat Genet 2009; 41: 1138-1143.
22. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007; 104: 20007-20012.
23. Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis 1999; 19: 243-252.
24. She X, Cheng Z, Zollner S, Church DM, Eichler EE. Mouse segmental duplication and copy number variation. Nat Genet 2008; 40: 909-914.
25. Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, Nishikawa Y, et al. Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int 2005; 25: 380-388.
26. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, et al. Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med 2005; 37: 276-281.
27. Miyagawa K, Sakakura C, Nakashima S, Yoshikawa T, Kin S, Nakase Y, et al. Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res 2006; 26: 3633-3643.
28. Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan YL, et al. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res 2010; 316: 149-157.
29. He N, Park K, Zhang Y, Huang J, Lu S, Wang L. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 2008; 134: 793-802.
30. Zhang Y, Xu P, Park K, Choi Y, Moore DD, Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. HEPATOLOGY 2008; 48: 289-298.
31. Zhang Y, Soto J, Park K, Viswanath G, Kuwada S, Abel ED, et al. Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth. Mol Cell Biol 2010; 30: 1341-1356.
32. Nejak-Bowen KN, Thompson MD, Singh S, Bowen WC Jr, Dar MJ, Khillan J, et al. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. HEPATOLOGY 2010; 51: 1603-1613.
33. Zhang XF, Tan X, Zeng G, Misse A, Singh S, Kim Y, et al. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. HEPATOLOGY 2010; 52: 954-965.
34. Hadjihannas MV, Behrens J. CIN By WNT: growth pathways, mitotic control and chromosomal instability in cancer. Cell Cycle 2006; 5: 2077-2081.
35. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-1773.
36. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007; 26: 774-780.
37. Maggioni M, Coggi G, Cassani B, Bianchi P, Romagnoli S, Mandelli A, et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. HEPATOLOGY 2000; 32: 942-946.
38. Sun M, Eshleman JR, Ferrell LD, Jacobs G, Sudilovsky EC, Tuthill R, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. HEPATOLOGY 2001; 33: 1415-1424.
39. Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004; 126: 1374-1386.
40. Sargent LM, Zhou X, Keck CL, Sanderson ND, Zimonjic DB, Popescu NC, et al. Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol 1999; 154: 1047-1055.
41. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76.
42. Chuang LS, Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605-2615.
43. Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K, Ito Y, et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem 2010; 285: 16693-16703.
44. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28: 220-224.
45. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007; 67: 863-867.
46. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007; 28: 940-946.